title: Treatment at discharge after myocardial infarction in 2,102 patients. The PRIMA study. Prise en charge de l'Infarctus du Myocarde Aigu.
abstract: OBJECTIVE
  This study sought to examine the use of treatments at discharge in patients hospitalized for myocardial infarction in a French region.
  
  
  RESULTS
  Data from 2,102 patients discharged after myocardial infarction were prospectively collected at 48 university, community, and private hospitals in three departments in the Rh ne-Alpes region between September 1, 1993 and January 31, 1995. Beta-blockers were prescribed in 59% of the patients, calcium channel blockers in 22%, nitrates in 59%, antiplatelet agents in 82%, anticoagulants in 26%, angiotensin-converting enzyme inhibitors in 36%, diuretics in 33%. Beta-blockers were prescribed less often in older patients, and in patients with higher Killip classes or a history of pulmonary disease. Calcium channel blockers were prescribed more often in older patients, and in patients with a history of diabetes, pulmonary disease, or non-Q wave myocardial infarction. Nitrates were prescribed more often in older patients. Angiotensin-converting enzyme inhibitors were prescribed more often in patients with a history of diabetes, hypertension, or anterior myocardial infarction, and less often in patients with a history of renal failure. Diuretics were prescribed more often in older patients, and in patients with a history of renal failure, diabetes, hypertension, or higher Killip classes.
  
  
  CONCLUSIONS
  There is still underuse of beneficial treatments, particularly in elderly patients.
authors: H pital Cardiovasculaire et Pneumologique Louis Pradel, Lyon, France.
authors: S
authors: S
authors: Excoffier
authors: G
authors: G
authors: De Gevigney
authors: R
authors: R
authors: Ecochard
authors: M
authors: M
authors: Rabilloud
authors: D
authors: D
authors: Cao
authors: E
authors: E
authors: Cheneau
authors: H
authors: H
authors: Milon
authors: F
authors: F
authors: Delahaye
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004070:Digitalis / Q000627:therapeutic use; D019468:Disease Management; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D009566:Nitrates / Q000627:therapeutic use; D016017:Odds Ratio; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D004232:Diuretics; D009566:Nitrates; D010975:Platelet Aggregation Inhibitors